Bioatla Inc

General ticker "BCAB" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $71.4M

Bioatla Inc does not follow the US Stock Market performance with the rate: -18.1%.

Estimated limits based on current volatility of 17.4%: low 0.74$, high 1.05$

Factors to consider:

  • Company does not operate outside North America (retrieved using AI)
  • Current price 53.4% below estimated low
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.31$, 3.82$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.34$, 3.81$]

Financial Metrics affecting the BCAB estimates:

  • Negative: Non-GAAP EPS, $ of -2.59 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -54.58 <= 2.35
  • Negative: negative Net income
  • Positive: Inventory ratio change, % of 0 <= 0
  • Positive: Interest expense per share, $ of 0 <= 0

Similar symbols

Short-term BCAB quotes

Long-term BCAB plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.25MM $0.00MM $0.00MM
Operating Expenses $96.69MM $108.14MM $129.69MM
Operating Income $-96.44MM $-108.14MM $-129.69MM
Non-Operating Income $1.04MM $1.66MM $6.22MM
Interest Expense $0.00MM $0.00MM $0.00MM
R&D Expense $58.27MM $79.35MM $103.73MM
Income(Loss) $-95.40MM $-106.48MM $-123.46MM
Profit(Loss) $-95.40MM $-106.48MM $-123.46MM
Stockholders Equity $210.82MM $180.34MM $70.67MM
Assets $254.42MM $225.74MM $119.66MM
Operating Cash Flow $-62.21MM $-90.42MM $-104.02MM
Capital expenditure $0.92MM $0.27MM $0.10MM
Investing Cash Flow $-0.92MM $-0.27MM $-0.10MM
Financing Cash Flow $69.51MM $61.21MM $0.08MM
Earnings Per Share* $-2.76 $-2.70 $-2.58

* EPS are Split Adjusted, recent splits may be reflected with a delay.